Background: Necroptosis plays a key role in cancer treatment. Mounting evidence suggests that many kinds of drugs can promote necroptosis in various tumor cells. Patients with bladder cancer (BLCA), especially those with advanced stage cancer, have a short life span; thus, new drugs need to be developed urgently to improve the situation. Long noncoding RNAs (lncRNAs) are considered regulatory targets for cancer, including BLCA. Therefore, we constructed a promising signature of lncRNAs related to necroptosis and further predicted the immune response and sensitivity of drugs. Methods: We downloaded the transcriptome and clinical data for BLCA from the Cancer Genome Atlas(TCGA). The expression network was constructed using coexpression analyses. Necroptosis related to lncRNAs (nrlncRNAs) was subsequently identified by univariate Cox regression. We then constructed the signature by performing the least absolute shrinkage and selection operator(LASSO) and evaluated it by Kaplan–Meier analysis, multivariate Cox regression, time-dependent receiver operating characteristics (ROC), nomogram, calibration curves, gene set enrichment analyses(GSEA), immune checkpoint, tumor microenvironment(TME), N6-methyladenosine (m6A) modification genes, and the half-maximal inhibitory concentration (IC50) analysis in the risk groups. The set was then divided into two groups according to nrlncRNAs expression in the different types. Results: We analyzed the survival features and principal component analysis (PCA) between the two groups. A 11-nrlncRNAs (AC008750.1, AL133297.1, AC005479.1, AP003559.1, UBE2Q1-AS1, MIR100HG, LINC02709, AC005387.1, LINC00649, AC021321.1, ETV7-AS1) prognostic signature was constructed. There was a significant difference in overall survival (OS) between the high-and low-risk groups (p < 0.001). The ROC curve exhibited the robust prognostic features of the signature. In addition, immune checkpoint analysis revealed that the expression of most of the immune genes in the high-risk group was higher than those in the low-risk group. FTO, ALKBH5, METTL3, and YTHDC1 were significantly different between the high-and low-risk groups in m6A regulators. The signature predicted different IC50 values to have statistical significance in high-and low-risk groups for multiple drugs, including cisplatin, docetaxel, gefitinib, and imatinib. Conclusions:In conclusion, our constructed signature may contribute to the prognosis of patients with BLCA as well as serve as clinical predictors of chemotherapy and immunotherapy.